论文部分内容阅读
目的 观察早期及延迟应用布地奈德对支气管哮喘 (简称哮喘 )小鼠气道炎症和气道重塑的防治作用。方法 40只小鼠分为 5组,每组 8只。鸡卵白蛋白(OVA)致敏 /激发组 (A组 ),生理盐水对照组(B组),布地奈德 (BUD)早期治疗组 (C组 ),BUD延迟治疗组 (D组 ),OVA延迟对照组(E组)。小鼠于第 0、14天以OVA致敏,从第 1次致敏后第 24天开始雾化吸入 2.5%的OVA激发并持续 18d,建立气道重塑模型;分别在早期(抗原激发前 1d始)和延迟(第 1次抗原激发后第 18天始)雾化吸入BUD(0.5mg/ml),观察抗原激发及BUD应用后支气管肺泡灌洗液(BALF)中嗜酸粒细胞(EOS)数、上清液白细胞介素 5(IL-5)和γ干扰素 (IFN-γ)水平的变化,同时对肺组织切片行苏木精 伊红(HE)、过碘酸雪夫(PAS)、Masson三色染色,测定支气管壁周围EOS计数、定量杯状细胞百分比及黏液分泌评分并测定气道平滑肌增生高度及胶原面积。结果 经过反复抗原激发,A组BALF中EOS数为(57.460±11 060)×104 /ml,B组为[ (0.050±0.020)×104 /ml],两组比较差异有统计学意义(P<0.01);A组BALF中IL- 5水平及IFN -γ水平分别为(52.9±2.8)pg/ml、(39.5±3.2)pg/ml,B组分别为(16.8±1.5)pg/ml、(63.8±3.3)pg/ml,两组比较差异有统计学意义 (P<0.01 );A、B组支气管壁周围EOS数分别?
Objective To observe the early and delayed use of budesonide on bronchial asthma (asthma) mice airway inflammation and airway remodeling prevention and treatment. Methods 40 mice were divided into 5 groups, 8 in each group. (Group A), normal saline control group (group B), early treatment group of budesonide (group C), delayed treatment group of BUD (group D), delayed OVA Control group (group E). Mice were sensitized with OVA on day 0 and day 14. From the 24th day after the first sensitization, 2.5% OVA was inhaled for 18 days to establish airway remodeling model. (0.5 mg / ml) for 48 hours after the first antigen challenge, and the eosinophilic BUD (0.5 mg / ml) was inhaled. The eosinophils in bronchoalveolar lavage fluid (BALF) ), Interleukin 5 (IL-5) and interferon-γ (IFN-γ) levels in the supernatant of the lung tissue were measured. The lung tissue sections were treated with hematoxylin and eosin (HE), periodic acid Schiff (PAS) , Masson trichrome staining, counting EOS around the bronchial wall, quantifying goblet cell percentage and mucus secretion score, and measuring airway smooth muscle hyperplasia height and collagen area. Results After repeated antigen challenge, the number of EOS in BALF in group A was (57.460 ± 11 060) × 104 / ml and in group B was [(0.050 ± 0.020) × 104 / ml], the difference was statistically significant (P < 0.01). The levels of IL-5 and IFN-γ in BALF of group A were (52.9 ± 2.8) pg / ml and (39.5 ± 3.2) pg / ml respectively in group A and (16.8 ± 1.5) pg / 63.8 ± 3.3) pg / ml, the difference between the two groups was statistically significant (P <0.01); A, B group EOS number around the bronchial wall?